Xiaoni Kong

TL;DR: IL‐22 induces the senescence of HSCs, which express both IL‐10R2 and IL‐22R1, thereby ameliorating liver fibrogenesis, in addition to the previously discovered hepatoprotective functions of IL‐ 22.

TL;DR: The cytokines and small molecules that activate STAT3 in hepatocytes may have therapeutic benefits to treat acute liver injury, fatty liver disease, and alcoholic hepatitis, while blockage of STAT3 may have a therapeutic potential to prevent and treat liver cancer.

TL;DR: Recent advances in the function and principal mechanisms by regulating Nrf2 in liver diseases, including acute liver failure, hepatic ischemia–reperfusion injury (IRI), alcoholic liver disease, viral hepatitis, non-alcoholic fatty liver disease (NAFLD), non- alcoholic steatohepatitis (NASH), and hepatocellular carcinoma are discussed.

TL;DR: In livers of mice and patients with chronic HBV infection, inflammatory cells produce IL-22, which promotes proliferation of LPCs via STAT3, and these findings link inflammation with proliferation ofLPCs in patients withHBV infection.

TL;DR: Hepatocytes are the major cell type responsible for LCN2 production after bacterial infection or PHx, and this response is dependent on IL‐6 activation of the STAT3 signaling pathway, and plays an important role in inhibiting bacterial infection and promoting liver regeneration.